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ABSTRACT

Background and Significance. The leishmaniases are a diverse group of diseases with
four major clinical manifestations: cutaneous, mucocutaneous, visceral, and diffuse.
Approximately 21 Leishmania species and 30 sandfly vectors have been implicated in human
leishmaniasis. Leishmaniasis is endemic in 88 countries, 72 are developing countries. Currently,
350 million people live in leishmaniasis-endemic areas around the world. The true incidence of
the disease is not known. However, the estimated incidence for visceral leishmaniasis is 500,000
cases per year, and for cutaneous and mucocutaneous leishmaniasis 1.5-2 million cases per year.
Visceral leishmaniasis causes 70,000 deaths each year. In the Americas region, leishmaniasis
extends from the United States to Argentina excepting Canada, Uruguay and Chile. In 2006,
62,000 leishmaniasis cases were registered affecting mostly Brazil, Colombia, Paraguay,
Venezuela, Panama, Ecuador, and Peru. In the United States, cutaneous leishmaniasis has been
reported in the southern part of Texas and also among military personnel deployed to Iraq and
Afghanistan. The first and second line treatments are extremely toxic. Resistant to some of these
drugs is very high in some parts of the world.
The only immunizing intervention shown to be effective for preventing human cutaneous
leishmaniasis is Leishmanization (LZ), but is not currently recommended due to a small number
of complications, such as non-healing lesions, and cases of immunosuppression following LZ.
First generation and second generation vaccines are difficult to standardize from cultured
parasites. Third generation vaccines using DNA are one of the most promising new
developments in vaccination strategies. The introduction of DNA plasmids into the cells of living
hosts has the potential to lead to the generation of both humoral and cellular immune responses

v

and protective immunity. DNA vaccination provides specificity, stability, safety, and a cost
advantage.
A leishmaniasis vaccine should optimally be composed of several molecules in order to
attack the survival mechanism of the parasite. This is because Leishmania parasites have
multiple molecules allowing them to enter the host cells and attack the body. For this study, the
molecules selected were biopterin transporter (BT), intracellular adhesive molecules (ICAMs),
ORFF, and Amastin. Biopterin Transporter is a potential growth promoter of Leishmania
parasites. Cell adhesion molecules (ICAMs) allow the survival of the parasite inside the cell. The
ORFF gene is reported to induce partial protection against challenge with L. donovani. The
Amastin family plays a role in adjusting the cytoplasmic pH allowing the survival of Leishmania
parasites inside the cells. For the present study, the BT, ICAM, ORFF, and Amastin antigens
were assembled in the pVAX backbone as a bicistronic plasmid in order to examine the polyantigen vaccination approach. The ability of these molecules to induce immunity and protection
was evaluated using a murine model.
Study Objectives. The two major objectives of this experimental phase 0 trial were: (1)
to characterize the immune response induced by the DNA vaccine candidate against L. mexicana
infection in a murine model, and (2) to determine the efficacy of the DNA vaccine candidate in
immunized BALB/c mice challenged with virulent L. mexicana promastigotes.
Hypothesis. It was hypothesized that the use of a cocktail DNA vaccine would induce
protection against L. mexicana infection in BALB/c mice by promoting the activation of
protective Th1-related cytokines and decreasing the progression of the disease at infected
footpad sites.
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Methodology. The experimental design used 29, six-week old BALB/c female mice. The
experimental and control groups were housed under identical environmental conditions. The
mice were randomized to one of the six experimental or control groups. The three experimental
groups were immunized with 100µL of pVAX-BT-ICAM, 100µL of pVAX-ORFF-Amastin, or
100µL of pVAX-BT-ICAM plus pVAX-ORFF-Amastin. The negative control groups were
injected with 100µL PBS or 100µL of pVAX. Three weeks after their last immunization, the
experimental and control groups were challenged subcutaneously in the left hind footpad with 40
µl of 1 x 106 stationary phase virulent L. mexicana promastigotes (LV4 strain). The development
of footpad lesions at the infection site was measured weekly for eight weeks. Quantitative Real
Time Polymerase Chain Reactions (QRT-PCR) assays were run to quantify gene expression of
Th1 indicators (Interleukin-2 Tumor Necrosis Factor-α, and Interferon-γ) and Th2 (Interleukin-4)
indicator. The data were analyzed using descriptive and bivariate statistical techniques.
Results. A partial protection and Th1 immune response was suggested in the
experimental group receiving the pVAX-BT-ICAM plus pVAX-ORFF-Amastin vaccine
candidate. This group had the smallest mean footpad lesion ( x = 0.465 ± 0.10). There was found
statistically significant reduction in footpad thickness when this group was compared to the other
experimental groups [pVAX-BT-ICAM (P = 0.000) or pVAX-ORFF-Amastin (P = 0.032)] and
to the negative controls [PBS (P = 0.032) or pVAX (P = 0.015)]. The group vaccinated with
pVAX-BT-ICAM plus pVAX-ORFF-Amastin had a Th1 cytokine profile (high levels of IL-2,
TNF-α, and IFN-γ) which is associated with immune protection against L. mexicana. However,
there was also an increased IL-4 expression. For this group, no statistically significance
differences were found between this group cytokine profiles (P = 0.376).
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Conclusion. Only the pVAX-BT-ICAM-I plus pVAX-ORFF-Amastin vaccine
formulation provided partial protection in BALB/c mice. This vaccine formulation was able to
decrease parasite burden better than single bicistronic plasmids at the end of the eight-week
follow-up period. The lymphocytes of the group vaccinated with pVAX-BT-ICAM-I + pVAXORFF-Amastin had a predominant Th1 immune response by showing higher levels of IFN-γ,
TNF-α, and IL-2. However, this protective cytokine profile was reduced by the presence of IL-4
which correlates to a partial protection observed after the eight-week follow-up. Hence, in order
to successfully attack L. mexicana, the vaccine must be composed of several antigens. Further
studies need to be conducted to support these findings as well as to evaluate the efficacy of this
vaccine in other Leishmania species causing cutaneous leishmaniasis clinical form.
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CHAPTER I: BACKGROUND AND SIGNIFICANCE

1.1 Leishmania Species
Leishmaniasis is a chronic infection caused by obligated intracellular protozoan parasites
of the genus Leishmania. Leishmaniasis causes several clinical forms resulting in the formation
of ulcerative skin lesions, partial or total destruction of the mucous membranes, or damage of
internal organs (Schwartz et al., 2006). The taxonomic classification is the following: Phylum:
Sarcomastigophora; Order: Kinetoplastida; Family: Trypanosomatidae; Genus: Leishmania and;
Subgenus: Leishmania and Viannia (Banuls et al., 2007). The two subgenera are separated on the
basis of the parasite location in the vector’s intestine (Jeronimo et al., 2006). Species belonging
to the subgenus Viannia develop in the hindgut before migrating to the midgut and foregut of the
vector. But, species belonging to the subgenus Leishmania only occupy the midgut and foregut
of the vector. Isoenzyme analysis, molecular methods, and monoclonal antibodies are used to
define species complexes within the subgenera. Species of the subgenus Viannia correspond to
those found in the New World including L. V. braziliensis, L. V. panamensis, L. V. guyanensis,
and L. V. peruviana, while those in the subgenus Leishmania correspond to the Old World
including L. L. donovani, L. L. tropica, L. L. major, L. L. aethiopica, L. L. infantum, and New
World L. L. mexicana, L. L. venezuelensis, L. L. amazonensis, and L. L. chagasi (Banuls et al.,
2007).
1.2 Leishmania mexicana
L. mexicana is widely distributed throughout Central and South America, up through
Mexico, South Texas and more recently North Texas and Oklahoma (Drisdelle, 2007). In
Mexico, cutaneous leishmaniasis is caused by L. mexicana and is endemic in 22 states. The most
1

affected areas are the southern and southeastern states of the country, mainly Veracruz, Tabasco,
Chiapas and Yucatán (Sanchez-Garcia et al., 2010). In 2008, within the Dallas-Fort Worth area,
9 patients presented with cutaneous leishmaniasis; 2 of these cases were caused by L. mexicana
species (Wright et al., 2008).
1.3 Leishmania Morphology
Leishmania parasites exist in two main morphological forms: amastigote and
promastigote. Amastigotes are round or oval bodies ranging from 2-4 µm in diameter with an
internalized flagellum (Jeronimo et al., 2006). Amastigotes are located in the parasitophorous
vacuoles of the host’s macrophages. The promastigotes exist as elongate, 10-15 µm, flagellated
forms, having a flagellum measuring 15-28 µm in length (Jeronimo et al., 2006).
1.4 Life Cycle
All species follow the same parasitic life cycle, alternating between the above-mentioned
forms (promastigote and amastigote) (Bellatin et al., 2002). Human infection begins with the
injection of promastigotes to the mammalian host during a blood meal (Figure 1). Once the
promastigotes are inside the host, these will be phagocytized by macrophages. Inside
macrophages, promastigotes transform into amastigotes. Amastigotes divide by simple division
and move to infect other mononuclear phagocytic cells (CDC, 2009). The sandfly infection stage
begins when the female sandfly becomes infected when feeding on the blood of an infected
individual or an animal reservoir host. At this stage, parasites reach the intestinal track within
sandfly as amastigotes (Jeronimo et al., 2006). Amastigotes are liberated into the fly midgut, and
within few hours are transformed into promastigotes. Then, promastigotes migrate forward to the
pharynx, buccal cavity, and mouthparts of the sandlfy. At 8 to 20 days, promastigotes are
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released into the bite wound during the sandfly’s blood meal (Wittner & Tanowitz, 2000). If
female sandflies ingest infected blood, the life cycle will repeat (Drisdelle, 2007).
1.5 Clinical Manifestations
There are four major clinical manifestations of leishmaniasis: cutaneous, mucocutaneous,
diffuse cutaneous, and visceral.
Cutaneous leishmaniasis (CL) varies by clinical severity and appearance, and time to cure
(Reithinger et al., 2007). The lesions appear within several weeks or months after the bite of an
infected sandfly, and it is frequently self-healing. Species causing CL are: L. major, L. tropica, L.
aetipica, L. panamensis, L. mexicana, L. braziliensis, L. guyanensis, L. amazonensis, and L.
peruviana.
Mucocutaneous leishmaniasis (MCL) usually develops as a complication of cutaneous
leishmaniasis in which parasites spread from the skin lesion via lymphatic vessels and blood to
reach the upper respiratory tract mucosa. Untreated lesions can result in deformities caused by
the destruction of the oral-nasal and pharyngeal cavities (Ahluwalia et al., 2004). Mucocutaneous
leishmaniasis is usually caused by L. braziliensis and L. panamensis.
Diffuse cutaneous leishmaniasis (DCL) occurs in individuals with defective cellmediated immune response. Lesions do not ulcerate, but instead nodules or plaques are formed
because amastigotes disseminate to skin macrophages forming a large number of lesions
(Wittner & Tanowitz, 2000). This form of leishmaniasis has no known cure. Diffuse cutaneous
leishmaniasis is caused by L. mexicana and L. amazonensis.
Visceral leishmaniasis (VL) is the most severe clinical form. Parasites infect
macrophages of the liver, spleen and bone marrow. Patients become gradually ill over a period of
a few months. The disease is usually fatal if left untreated with first, second, or third line drugs
3

(Boelaert et al., 2000). Untreated VL is fatal in 75 to 85 percent of infantile and 90 percent of
adult cases. Visceral leishmaniasis is caused by L. donovani, L. infantun in the Old World, and
by L. chagasi in the New World.
1.6 Vector
The vector for leishmaniasis is a female sandfly of the genera Phlebotomus in the Old
World and Lutzomyia in the New World. The sandflies are 2-3 mm long and usually found in
tropical and temperate zones (Sharma & Singh, 2008). The sandfly larvae require organic matter,
heat, and humidity for the growth, development, and reproduction. They live in moist soil,
stonewalls, garbage dumps, and cracks in house walls. Typically, sandflies have a crepuscular
activity after feeding at early night or early morning while the host is asleep (Campbell, 2000).
However, the hours in which sandflies are most active depends upon the species. In Mexico, the
only proven vector of L. mexicana is Lu. olmeca olmeca (Sanchez-Garcia et al., 2010). In the
United States, two vectors have been identified for L. Mexicana: Lu. Anthophora and Lu.
diabolica (Gonzalez et al., 2010).
1.7 Reservoir
The reservoirs for human leishmaniasis in endemic areas of the Old World include
humans as well as numerous rodent and canine species (Sharma & Singh, 2008). However, in the
New World, leishmaniasis is a zoonotic disease. Reservoirs include forest rodents, sloths,
armadillos, and dogs (Gramiccia & Gradoni, 2005). For L. Mexicana, Ototylomys phyllotis (the
tree rat) is the primary host in Belize and the Yucatan peninsula in Mexico (Gramiccia &
Gradoni, 2005; Saliba & Oumeish, 1999). In Texas, Neotoma micropus (the wood rat), has been
found to be naturally infected with L. mexicana (McHugh et al., 2003). According to McHugh
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and associates (2003), the first known the human cases of leishmaniasis were attributed to
residence in or travel to the habitat in which N. micropus, the reservoir host in Texas, lives.
1.8 Epidemiology
The leishmaniases are a diverse group of diseases. Approximately 21 Leishmania species
and 30 sandfly vectors have been implicated in human leishmaniasis (Desjeux, 2004).
Leishmaniasis is endemic in 88 countries, 72 are developing countries. Currently, 350 million
people live in leishmaniasis-endemic areas around the world (WHO, 2012a). The true incidence
of the disease is not known. However, the estimated incidence for visceral leishmaniasis is
500,000 cases per year, and for cutaneous and mucocutaneous leishmaniasis is 1.5-2 million
cases per year (WHO, 2012a). Visceral leishmaniasis causes 70,000 deaths each year (Reithinger
et al., 2007).
In the Americas region, leishmaniasis extends from the United States to Argentina
excepting Canada, Uruguay and Chile (CDC, 2010). In 2006, 62,000 leishmaniasis cases were
registered in the Americas affecting mostly Brazil, Colombia, Paraguay, Venezuela, Panama,
Ecuador, and Peru (PAHO, 2007). More than 5,000 visceral leishmaniasis cases were reported,
most of these from Brazil (WHO, 2012a).
In the United States, cutaneous leishmaniasis has been reported in the southern part of
Texas and also among military personnel deployed to Iraq and Afghanistan (Leder & Weller,
2010). Approximately 700 cases due to L. major have been reported for U.S. military personnel
serving in Iraq (CDC, 2009). In 2008, within the Dallas-Fort Worth complex, nine individuals
were diagnosed with cutaneous leishmaniasis (Wright et al., 2008). There are several reasons the
burden of the disease might be underestimated. For instance, the site of transmission within
endemic areas are often discontinuous, numerous cases are undiagnosed, misdiagnosed or
5

unreported, especially in places without access to medical facilities, and public health authorities
receive poor quality and quantity of information from the field (Desjeux, 2004).
1.9 Modes of Transmission and Risk Factors
Cutaneous leishmaniasis is most commonly transmitted through the bite of an infected
sandfly vector. It can also occur through accidental laboratory exposure but this is rare (Wittner
& Tanowitz, 2000). In the New World, the main risk factors related to cutaneous leishmaniasis
are urbanization, deforestation and new settlements, agricultural development with the building
of dams and new irrigation schemes, and for military exercises (Desjeux, 2001; CDC, 2009).
1.10 Immune Response
Leishmania parasites normally reside within macrophages and dendritic cells because
these serve as safe habitats (Bogdan et al., 1996). Parasites survive and replicate inside these
cells by modulating the normal antimicrobial machinery of the macrophages and dendritic cells
(Selvapandiyan et al., 2012). They are able to enter macrophages cells via receptor-mediators
including complement receptor 1 (CR1) and complement receptor 3 (CR3). These allow cell
entry without activation of oxidative burst (Alexander et al., 1999). The survival of the parasites
is also mediated by Leishmania surface molecules which appear to inhibit superoxide and nitric
oxide species (Bellatin et al., 2002). Thus, Leishmania parasites are able to interfere with various
steps of the inflammatory process, which might delay or even block the development of a
protective immune response (Bogdan & Rollinghoff, 1998).
Leishmania parasites rely on the phagocytic capacity of host cells in order to gain entry
into the cell (Rittig & Bogdan, 2000). For all Leishmania species, immunologists have found that
macrophages, dendritic cells, CD4+ type 1 T helper cells type one (Thl), cytokines such as
Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-2 (IL-2), and
6

transcription factors such as Interferon-Regulatory-Factor-l (IRF-I), are key for the control of
infections and for a long-lasting protective immunity (Bogdan & Rollinghoff, 1998).
Previous studies have identified two immunoregulatory subsets of murine CD4+ cells
influencing the outcome of infection (Pirmez et al., 1993). The first immunoregulatory subset is
T helper cells type one (Th1). T helper cells type 1 related cytokines secretions appear to be
crucial for host control of parasite burden and clinical cure (Castellano et al., 2009). For this kind
of immune response, Th1 cells enhance cell-mediated immune responses by activating
macrophages to kill or inhibit the growth of Leishmania. The Th1 response results in mild or
self-curing disease. T helper cells type one (Th1) secrete IFN-γ, TNF-α, and IL-2 (Roberts,
2005). The second one is T helper cells type 2 (Th2) immune response. T helper cells type 2
enhance humoral immunity and down regulate cell-mediated immune response (Th1), which
results in disease progression and dissemination of Leishmania infection. These Th2 cell
populations secrete Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-10 (IL-10),
Interleukin-13 (IL-13) (Roberts, 2005).
The production of IFN-γ leads to intracellular death of amastigotes through a common
effector mechanism present in activated macrophages (Roberts, 2005). Interferon-gamma (IFNγ) (from Th1 cells) mediate macrophage activation, nitric oxide production and parasite killing
(Alexander & Bryson, 2005). Furthermore, TNF-α is a potent pro-inflammatory mediator related
to tissue damage events and inflammatory cell recruitment to the local site of infection
(Castellano et al., 2009). However, IL-2 does not mediate macrophage activation directly. It is
responsible for inducing T helper cells proliferation as well as exerting broad immunoregulatory
effects on T cells and natural killer cells, and stimulating IFN-γ secretion. Interleukin-2 (IL-2)
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also induces protective effects against intracellular infections and has been used as treatment in
infected patients (Murray et al., 1993).
1.11 Leishmania Relevant Molecules
Leishmania parasites have multiple molecules allowing them to enter the host cells and
attack the body (Banuls et al., 2007). These molecules include glycosylphosphatidylinositol
(GPI), glycosylphospholipid (GIPL), lipophosphoglycans (LPG), phosphoglycans (PG),
leishmanolysin (gp63), and cysteine proteases (CPs) (McGwire et al., 2002). All of these
molecules appear to play important roles in Leishmania infection of macrophages since they are
involved in the binding, migration and release of the parasite in the sandfly midgut and in the
modulation of resistance to lysis by the host complement (McGwire et al., 2002).
Lipophosphoglycans (LPG) are also responsible for the binding and uptake by macrophages,
modulating macrophage signal transduction, resistance to oxidative attack, and for allowing the
parasite to establish successful infections (Beverley & Turco, 1998). Leishmanolysin (gp63) is
involved in the intracellular survival of the parasite within host macrophages (McGwire et al.,
2002). For this study, the molecules selected were biopterin transporter (BT), intracellular
adhesive molecules (ICAMs), ORFF, and Amastin.
Biopterin transporter is the molecule encoding the transport of biopterin (BT). Biopterin
transporter (BT) may be a potential growth promoter for Leishmania cells. The exact role of BT
is unknown. Biopterin transporter (BT) is essential for parasite survival, because this gene
encodes the transport of biopterin which is an essential nutrient for the parasite (Lemley et al.,
1999). Cell adhesion molecules (CAMs) play a key role in stabilizing and strengthening cell-tomatrix and cell-to-cell interactions (Chiang et al., 2002). Additionally, ICAMs interact with
receptors in macrophages allowing the survival of the parasite inside the cell (Ng et al., 2009).
8

Previous studies have identified purified recombinant ORFF (rORFF) protein in the
serum from patients with VL. After immunization of mice with rORFF protein, investigators
were able to demonstrate partial protection against challenge with L. donovani (Sukumaran et al.,
2003). Researchers also were able to identify ORFF in the multigene LD1 locus in all
Leishmania isolates: the LD1 locus is a 27.5-kb region of chromosome 35 (Ghosh et al., 1999).
Amastins belong to a large family of surface proteins and have been discovered in the
Leishmania genus (Rafati et al., 2006). There are approximately 45 members of the Amastin
gene family dispersed through the Leishmania genome. Amastin usually code for small proteins
composed of about 200 amino acids (Rochette et al., 2005). Due to its relative hydrophobic
sequence and its localization in the membrane, the Amastin family plays a role in proton or ion
traffic across the membrane adjusting the cytoplasmic pH for the survival of Leishmania
parasites inside the cells (Rafati et al., 2006). Nonetheless, the role of the Amastin family with
respect to Leishmania virulence remains unclear. A study conducted by Rafati et al. (2006)
showed an Amastin antibody response specific for the active stage of visceral leishmaniasis
patients. However to date, no attempts have been made to utilize this molecule as a cutaneous
leishmaniasis vaccine candidate.
1.12 Available Treatments
The first line drug treatments for cutaneous and visceral leishmaniasis were first
developed over 60 years ago (Croft et al., 2006). Currently, no single drug is able to cure all
clinical forms of leishmaniasis (Croft et al., 2006; Minodier & Parola, 2007; Reithinger et al.,
2007). Disease prognosis varies by species and the immune status of the human host (Croft &
Coombs, 2003). Unfortunately, species identification using culture and isoenzymatic
examination methods is difficult and time consuming (Minodier & Parola, 2007). In addition
9

new rapid diagnostic tools, such as genomic amplification by the polymerase chain reaction, are
still not widely available (Minodier & Parola, 2007). Clinicians usually initiate treatment by
assuming patients were infected with the parasite living in that specific geographical setting
(Reithinger et al., 2007). Few drugs are available to treat leishmaniasis and these have various
shortcomings.
The first line treatment is pentavalent antimony. This has long been the cornerstone of
anti-leishmaniasis chemotherapy and still plays a leading role in treatment (Minodier & Parola,
2007; Ouellette et al., 2004). However, resistance to this drug is very high in some parts of the
world, particularly in North East India (Ouellette et al., 2004)
Second-line drugs for leishmaniasis include pentamidine isethionate and amphotericin B
but these are used less often due to toxicity and cost issues (Minodier & Parola, 2007).
Pentamidine isethionate is used in South America for cutaneous leishmaniasis, especially for CL
caused by L. guyanensis (Minodier & Parola, 2007). Amphotericin B (AmB) has been used in
place of antimonial drug treatment. The polyene AmB is a second-line antifungal drug used to
treat systemic fungal infection (Ouellette et al., 2004). AmB is extremely toxic and is associated
with severe side effects. However, newer lipid formulations of AmB appear less toxic while
maintaining anti-leishmaniasis properties (Minodier & Parola, 2007). These new lipid AmB
formulations are unaffordable for a majority of affected populations in endemic developing
countries (Ouellette et al., 2004).
Paromomycin and localized controlled heat (LCH) have been used as topical treatments
for CL (Croft et al., 2006; Minodier & Parola, 2007). An ointment prepared with 15%
paramomicyn sulfate and with 12% methylbenzonium chloride was found to be effective in
treating CL cause by L. mexicana in Belizian patients, and L. mexicana and L. braziliensis in
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Guatemalan patients (Minodier & Parola, 2007). In other study, ointments prepared with 15%
paramomicyn sulfate plus 12% methylbenzonium chloride (PR-MBCL) and 15% paramomicyn
sulfate plus 10% urea (PR-U) were compared to meglumine antimoniate (MA) (Armijos et al.,
2004a). After 12 weeks, the proportion of clinically cured participants in the MA (91.7%)
compared to PR-MBCL (79.3%) and PR-U (70%) groups was found to be not statistically
significant different. Localized controlled heat (LCH) has been used to treat L. mexicana
infections. The FDA has approved the use of the ThermoMed® (ThermoSurgery Technologies,
Inc, Phoenix, Arizona) device which delivers localized radio frequency-generated heat directly to
the lesion by placing prongs onto it (Minodier & Parola, 2007). The procedure is painful and
requires the application of a local anesthetic. Heat may be controlled locally and it is applied for
30 seconds, reaching temperatures up to 50°C. It was reported as effective in treating L.
mexicana affecting Guatemala and Mexico with 90% healing in two months but this study was
not a controlled clinical trial (Velasco-Castrejon et al., 1997).
1.13 Development of Vaccines
Vaccination is considered the most promising intervention for preventing cutaneous
leishmaniasis in humans (Blackburn, 2006). A main rationale for the development of a vaccine
for CL is that individuals who have previously had leishmaniasis are resistant to subsequent reinfection (Reithinger et al., 2007). So far, there are no approved vaccines for leishmaniasis.
However, many investigators have been working on the development of a CL vaccine (Coler &
Reed, 2005; Khamesipour et al., 2006; Requena et al., 2004). The only immunizing intervention
shown to be effective for preventing human CL is Leishmanization (LZ), but is currently not
recommended by WHO (Reithinger et al., 2007). Leishmanization consists of injecting liveattenuated parasites in humans (Khamesipour et al., 2005). Leishmanization was originally
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developed for used in Iran and Israel but is not currently practiced by either country (Handman,
2001; Khamesipour et al., 2005). In Iran, a national LZ campaign was halted due to a small, but
unacceptable number of complications such as non-healing lesions (Khamesipour et al., 2005).
In Israel, it was ceased due to some cases of immunosuppression resulting in reduced
responsiveness to pediatric diphtheria, pertussis, and tetanus vaccines following LZ
(Khamesipour et al., 2005).
Leishmaniasis vaccines are categorized as first generation, second generation, and third
generations. First generation leishmaniasis vaccines are made with killed whole parasites
(Modabber, 1995; Noazin et al., 2008). In general, these types of vaccines are relatively easy to
produce and low in cost. The primary disadvantage, of first generation vaccines, is the
complexity of standardizing vaccines derived from cultured parasites. Studies have been
conducted in Colombia, Ecuador, Venezuela, Brazil, Iran and Sudan with varying results using
first generation vaccines (Armijos et al., 1998; Mayrink et al., 2002; Velez et al., 2005).
A randomized, double-blind clinical trial was conducted in Colombia in order to examine
the immunogenicity and safety of three doses of a monovalent L. amazonensis (L-8 Brazilian
strain) vaccine with Bacille Calmette-Guèrin (BCG) used as an adjuvant against CL (Velez et al.,
2005). Participants were followed for twelve months. The overall incidence of CL was similar in
both the vaccinated and placebo groups (7.8% vs. 6.8%). Although the vaccine was safe and
immunogenic, it did not provide significant protection against CL infection.
Safety, immunogenicity and efficacy of two intradermal doses of a triple species vaccine
was assessed using two doses of BCG in Ecuador (Armijos et al., 1998). The promastigotes used
in the study were originally collected from the lesions of patients living in the study area and
were mixed with BCG to construct the vaccine (L. braziliensis, L. guyanensis, and L.
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amazonensis). Twelve months of follow-up revealed an efficacy of 73%. Subjects were followed
for 4 more years (Armijos et al., 2003). The vaccine provided protection between the 13th and
18th month, with an efficacy of 56.5%. However, from the 19th to the 60th month no statistical
significance was found different between the vaccine and control arm subjects. Later, a
randomized, blinded study was also conducted in Ecuador to examine the safety,
immunogenicity, and efficacy of two doses of an autoclaved-killed, whole cell Leishmania
amazonensis vaccine (IFLA/BR/67/PH8) with Bacille Calmette-Guèrin (BCG) used as an
adjuvant against CL infections (Armijos et al., 2004b). The overall incidence of CL was similar
in both the vaccinated and placebo groups (2.0% vs. 1.3%). However, the vaccine did not offer
significant protection against CL infection.
Second generation vaccines consist of defined protein antigens or recombinant protein
components. Only one second generation leishmaniasis vaccine has been evaluated in phase 1
and 2 clinical trials in humans (Coler & Reed, 2005). Three vaccine-candidate antigens were
selected to test a vaccine against CL and MCL (Skeiky et al., 2002). The molecules, LmSTI1,
TSA and LeIF, were selected because these are found in most Leishmania species causing
human disease (Skeiky et al., 1995). They also have been shown to elicit a Th1-type immune
response in mice and human cells (Probst et al., 1997; Skeiky et al., 1995; Webb et al., 1996).
The vaccine appeared to be safe and a majority of recipients showed a Thl immune response 4
weeks after the last immunization.
Third generation vaccines using DNA are one of the newest developments in vaccination
strategies (Pavlenko et al., 2004). The introduction of DNA plasmids into the cells of living hosts
has the potential to generate both humoral and cellular immune responses and protective
immunity (Dunning, 2009; Palatnik-de-Sousa, 2008; Ulmer et al., 1996). Some of the reported
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advantages of DNA vaccination include: specificity, non-immunogenicity of the plasmid vector,
mammalian post-translational modification, stability, safety, cost advantage, and generic
manufacturing (Dunning, 2009; Palatnik-de-Sousa, 2008; Ulmer et al., 1996).
Single antigen and multiple antigen DNA vaccines have been developed. Single antigen
DNA vaccines produce a stronger Th1 immune response, longer-lasting immunity, and/or a
better protection against the progression of the disease (Aguilar-Be et al., 2005; Iborra et al.,
2003; Rafati et al., 2006; Sjolander et al., 1998a; Sjolander et al., 1998b). Moreover, multiple
antigen DNA vaccines have proven to be more effective; however, this efficiency dependents on
the antigen combination (Dumonteil et al., 2003; Iborra et al., 2004; Mendez et al., 2002;
Mendez et al., 2001; Rosado-Vallado et al., 2005). Dumonteil and associates (2003) investigated
the efficacy of DNA vaccines by encoding L. mexicana antigens gp63, gp46, CPb, and LACK
with the purpose of determining the usefulness of DNA vaccines and define the most useful
antigens against L. mexicana. The study results suggested that DNA vaccines may be a useful
strategy since these offer partial protection against L. mexicana infection (Dumonteil et al.,
2003). Previous Phase 0 studies using pVAX-BT-ICAM and pVAX-ORFF-Amastin have shown
partial protection in susceptible BALB/c mice (Armijos et al., 2007).
Sukumaran et al. (2003) conducted a study for the purpose of examining the possibility of
using ORFF molecule for the development of a DNA vaccine. Their study findings suggested
that DNA vaccination with the ORFF molecule induced in a significant protection of BALB/c
mice against infection with L. donovani (Sukumaran et al., 2003). Protection reached its
maximum level at four weeks after infection, although immune memory persisted only eight
weeks. Hence, the ORFF molecule from the LD1 locus of Leishmania could represent an
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effective vaccine strategy against L. donovani infection. Many investigators have agreed that a
successful Leishmania vaccine will need to be based on multiple antigens (Dumonteil, 2007).
1.14 Study Rationale
Cutaneous leishmaniasis is a global public health threat. An estimated of 350 million
persons live in leishmaniasis-endemic areas and 1.5-2 million new cases occur each year (WHO,
2012a). Cutaneous leishmaniasis, along with other clinical forms, is one of 17 neglected tropical
diseases identified by the World Health Organization (WHO, 2012a). Leishmaniasis is a disease
of poverty associated with socioeconomic disparities and environmental degradation such as
deforestation, urbanization, dam-building, and monocrop agriculture (WHO, 2012b). Although
the cutaneous form of leishmaniasis rarely fatal, it has been linked with significant adverse such
as psychological consequences (e.g. low self-esteem, stress, anxiety, depression) (Weigel et al.,
1994; Weigel, 1996), social stigma and discrimination (Weigel et al., 1994; Weigel, 1996),
reduced work productivity (Weigel et al., 1994), reduced marriage prospects in females (Weigel
et al., 1994), secondary bacterial infection risk (Weigel et al., 1994), and child growth stunting
and iron-deficiency anemia (Weigel et al. 1995).
Current treatments for leishmaniasis are highly toxic and expensive. Drug-resistance has
been increasing in many parts of the world (Chakravarty & Sundar, 2010). Vaccination is
considered as the most effective type of preventive intervention (Blackburn, 2006). The use of
attenuated vaccines is not recommended because of the risk of reverting to virulent parasite
forms (Handman, 2001). Attenuated vaccines also have the potential for pathogenicity in
immunocompromised patients such as aging persons or those with TB or HIV/AIDS (Kedzierski,
2010). Furthermore, the transport of these types of vaccines to remote areas where leishmaniasis
is endemic can be difficult because of their cold storage requirements and need for mixing on site
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with adjuvant (Handman, 2001). In contrast, DNA vaccines offer potential higher specificity,
non-immunogenicity of the vector (plasmid), mammalian post-translational modification, better
stability, safety, cost advantage, and relatively easy manufacturing technology (Dunning, 2009;
Palatnik-de-Sousa, 2008; Ulmer et al., 1996). To date, most of the work done conducted on DNA
vaccines has used murine models, and these have shown some level of protection against
tuberculosis, smallpox, and other intracellular pathogens in mice models (Hunt, 2010).
Cutaneous leishmaniasis caused by L. mexicana is a good candidate for a DNA vaccine
since the immune system is able to generate memory cells, thus preventing re-infection
(Alexander & Bryson, 2005; Kemp et al., 1998). In order to be successful, the vaccine should
optimally be composed of several molecules attacking the different survival mechanisms used by
the parasite (Dumonteil, 2007). The present study used BT, ICAM, ORFF, and Amastin antigens
assembled in the pVAX backbone as a bicistronic plasmid in order to examine the promising
poly-antigen vaccination approach. The ability of these molecules to induce immunity was
evaluated in this study using a murine model.
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CHAPTER II: STUDY AIMS AND HYPOTHESES

2.1 Study Objectives
The major objective of the experimental study was to investigate the efficacy of a DNA
vaccine in preventing murine leishmaniasis caused by Leishmania mexicana.
2.2 Specific Aims
The first aim was to characterize the immune response induced by the DNA vaccine
candidate against L. mexicana infection in a murine BALB/c model. This was accomplished by
carrying out immunological assays to measure Th1 and Th2 cytokine levels in the immune
response against L. mexicana infection in BALB/c mice.
The second aim was to determine the efficacy of the DNA vaccine candidate in
immunized BALB/c mice challenged with virulent L. mexicana promastigotes. This was
accomplished by monitoring progression of the lesion in the infection site.
2.3 Hypothesis
It was hypothesized that the use of a cocktail DNA vaccine would induce protection
against L. mexicana infection in BALB/c mice by promoting the activation of protective Th1related cytokines and decreasing the progression of the disease at infected footpad sites.
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CHAPTER III: METHODS AND MATERIALS

3.1 Study Approval
The study protocol was approved by the UTEP Institutional Biosafety Committee
Recombinant DNA Protocol (IBC) on March 14, 2005 (Protocol #2005-02) and the UTEP
Institutional Animal Care and Use Office on September 7, 2006 (Protocol # A-200606-3)
3.2 Plasmid Design
The vaccine should optimally be composed of several molecules in order to successfully
attack the survival mechanisms of the parasite and using only one gene would potentially allow
the parasite to adapt more easily. The following four gene segments were selected because their
role in important aspects of Leishmania survival. Biopterin Transporter is a potential growth
promoter of Leishmania parasites (Lemley et al., 1999). Cell adhesion molecules (ICAMs)
interact with receptors in macrophages allowing the survival of the parasite inside the cell (Ng et
al., 2009). The ORFF gene is reported to induce partial protection against challenge with L.
donovani (Sukumaran et al., 2003). The Amastin family plays a role in proton or ion traffic
across the membrane adjusting the cytoplasmic pH for the survival of Leishmania parasites
inside the cells (Rafati et al., 2006).
The plasmids used in the present study were previously designed by Armijos and
associates using pVAX1 backbone (2007) (Figure 2 and Figure 3). The PCNV serves as the
promoter for BT and ORFF, meanwhile the internal ribosome entry site (IRES) reassures
expression of ICAM and Amastin. The restrictive enzymes Neh-I, Bam H1, Pst-1 and Xba-1
present in pVAX1 were digested to insert the four Leishmania’s gene segments. The stop codon
is BGHpA, whereas pUCORI is the stop codon. Kanamycin resistance gene is use for the
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selection in E. coli as well as to minimize allergic responses in hosts. The BT, ICAM, ORFF, and
Amastin genes were PCR-amplified from the L. mexicana genome and inserted into the cloning
site of pVAX1 (Invitrogen, cat No: V26020). A eukaryotic bicistronic expression vector, pVAX1
was specifically designed for the development of vaccines as per FDA recommendations for
plasmids used in DNA vaccines for preventable infectious diseases in humans (FDA, 1996).
3.3 Experimental Animals
The experimental (phase 0) design study used 29, six-week old BALB/c female mice
(Jackson Laboratory). The BALB/c mouse strain was selected for this study because of its
documented susceptibility to infection with L. mexicana (Padigel et al., 2003). The animals were
randomized to the experimental (n = 14) and the control (n = 15) groups. All animals were
housed under the same environmental conditions in the pathogen-free Vivarium located in the
UTEP Biology Building.
3.4 Study Protocol
There were three experimental and three control groups in the study (Table 1). All groups
were injected in the hind leg quadriceps using a one milliliter syringe with a 30 gauge, ½-inch
needle (BD Ultra-Fine needleTM). The experimental groups were immunized with 100µL of the
corresponding plasmid. The negative controls were injected with 100µL of PBS and pVAX,
respectively. The phosphate buffered saline (PBS) is not going to induce an immunological
response or provide protection to mice. The pVAX vector alone does not provide protection
against leishmaniasis (Masih et al., 2011). The groups received a total of three doses. Each dose
was administered every three weeks.
Three weeks after the last immunization, the experimental and control groups were
challenged subcutaneously in the left hind footpad with 40 µl of 1 x 106 stationary phase L.
19

mexicana promastigotes. The virulent LV4 strain was provided by Dr. Eric Dumonteil,
Universidad Autonoma de Yucatan. The development of footpad lesions at the infection site was
measured weekly for eight weeks. The measurements were expressed as the difference between
the thickness of the infected versus contra-lateral non-infected footpad on the same experimental
animal.
The experimental and control groups were sacrificed eight weeks after their initial
challenge with L. mexicana promastigotes in order to extract lymphocytes required to examine
the hypothesized the immunological response induced by the vaccines. Carbon dioxide
inhalation was used to euthanize the mice. As per the accepted protocol, the animals remained in
the CO2 chamber for approximately a minute, and death was verified by lack of cardiac pulse and
dilated pupils (AVMA, 2007)
3.5 Quantitative Real Time Polymerase Chain Reaction (QRT-PCR)
RNA Homogenization/Extraction/Purification (RiboPureTM Kit). Lymph node cells
were used to measure the immune response generated by the vaccine. Lymph node cells were
homogenized in 1ml TRI Reagent. The homogenate was incubated for five minutes at room
temperature, which was subsequently centrifuged 12,000 x g for 10 minutes at 4ºC. Supernatant
was transferred to a new tube. Two hundred microliters of chloroform was added per tube and
vortexed at maximum speed for 15 seconds. Tubes were incubated at room temperature for five
minutes and centrifuged at 12,000 x g for 10 minutes at 4ºC. Two layers were formed after tubes
were centrifuged. Then, four hundred microliters of the top layer was transferred to a new 1.5ml
microcentrifuge tube. Two hundred microliters of 100% ethanol was added and vortexed for five
seconds. The sample was passed through a filter cartridge and centrifuged at 12,000 x g for 30
seconds at room temperature. The flow-through was discarded and filter was returned to
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cartridge. Five hundred microliters of wash solution was added to the filter cartridge-collection
tube assembly. Once again, the cartridge-collection tube assembly was centrifuged for 30
seconds at room temperature and flow-through once more discarded and returned to original
collection tube. The cartridge-collection was washed once more followed by centrifugation for
30 seconds at room temperature. The filter cartridge was placed in a new collection tube and
50µl of Elution Buffer was added to filter column. Incubation at room temperature for two
minutes followed. The filter column was centrifuged for 30 seconds to elute the RNA from the
filter.
cDNA Reverse Transcription Reaction (iScriptTM cDNA Synthesis Kit). Ten
microliters of a 2X RT master mix was pipetted into each individual tube. Ten microliters of
RNA sample was added into each tube and pipetted up and down. The tubes were centrifuged
briefly to spin down contents and to eliminate air bubbles. The tubes were then placed in a
thermal heater (Table 2). Upon completion, samples were stored at the -80ºC freezer.
RT-PCR plate (Applied BioSystemsTM). The cytokines analyzed were TNF-α, IL-2, IL4, and IFN-γ. TaqMan probes were used for each of the cytokines and β-actin served as the
reference gene. Each well in a PCR plate included an amount of cDNA equivalent to 500 ng of
RNA, 1 µL TaqMan probe, 10 µL TaqMan Universal Master Mix, and an amount of nuclease
free water bringing the total volume in the well up to 20 µL. Once the plate was filled with the
samples to be analyzed, it was placed in an iCycler iQTM Optical Module thermal cycler
manufactured by BIO RAD with the appropriate thermal cycler program (Table 3).
3.6 Sample Size
The UTEP’s Institutional Animal Care and Use Committee recommend using a small
number of animals for ethical reasons (OLAW, 2002). The study was originally designed to have
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eight mice per group. However, the number of mice was reduced in certain groups due to
unforeseen technical difficulties. Specifically, the L. mexicana strain did not arrive on time. The
mice groups had previously received the three doses of the vaccine making a start time a high
priority. Thus, a decision was made by the supervising faculty, research mentor to use selected
mice for another investigation so as not to lose the mice. Thus, by the time the L. mexicana strain
arrived, those mice were already allocated to another study which reduced the sample size in
some groups.
3.7 Statistical Analysis
Data obtained by the QRT-PCR followed the Mean 2-ΔΔCT (Livak) Method in order to
obtain normalized expression ratios (Livak & Schmittgen, 2001). Data obtained on the weekly
progression of the foodpad lesions and the QRT-PCR were analyzed using descriptive statistics
in SPSS (Version 19). Data following a normal distribution were analyzed using the Repeated
Measures ANOVA. Data not normally distributed were analyzed using the Kruskal-Wallis Test.
Data are presented as the mean ± S.E.M.
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CHAPTER IV: RESULTS

4.1 Protective Effect of the DNA Vaccine
In order to determine whether vaccination with pVAX-BT-ICAM, pVAX-ORFFAmastin, or pVAX-BT-ICAM plus pVAX-ORFF-Amastin was able to confer protection,
vaccinated mice and controls were challenged with 40 µl of 1 x 106 stationary phase L. mexicana
promastigotes on their left footpads as discussed in the methodology section. The lesion progress
was measured weekly with a digital caliper. Lesion size was expressed as the mean difference
between the infected footpad and the contra-lateral uninfected footpad. Repeated measures
ANOVA using a generalized linear model was used for statistical comparison between groups.
At eight weeks, Group 3 (pVAX-BT-ICAM plus pVAX-ORFF-Amastin) had the
smallest mean difference footpad swelling between the infected and contra lateral footpad (Table
4). The results for Group 3 (pVAX-BT-ICAM plus pVAX-ORFF-Amastin) showed a
statistically significant reduction in footpad thickness when compared to the groups injected with
single bicistronic plasmids [(Group 1) pVAX-BT-ICAM ( x = 0.940mm ± 0.151; P = 0.000) or
(Group 2) pVAX-ORFF-Amastin ( x = 0.521mm ± 0.151; P = 0.032)] and to the negative
controls [PBS ( x = 0.465 ± 0.135; P = 0.032) and pVAX ( x = 0.489mm ± 0.130; P = 0.015)]
(Figure 4). Hence, the results suggested that pVAX-BT-ICAM plus pVAX-ORFF-Amastin
appeared to provide partial protection in mice.
4.2 Immune Response to the DNA Vaccine
A robust Th1 immune response is required to confer adequate protection against
Leishmania infection (Alexander & Bryson, 2005; Dumonteil et al., 2003). In order to
characterize the type of immune response generated by pVAX-BT-ICAM plus pVAX-ORFF23

Amastin, the relative expression of IL-2, TNF-α, IFN-γ and IL-4 from regional lymph nodes was
analyzed using quantitative RT-PCR (Applied BiosystemsTM). Kruskal-Wallis Test was used for
statistical comparison between groups.
The results of the study showed a mixed Th1/Th2 immune response for Group 1 (pVAXBT-ICAM) (Figure 5). The cytokines profiles of Group 1 were compared but there was not
statistical difference (P = 0.367). Moreover, Group 1 was compared to negative controls, PBS
and pVAX, but no statistically significant differences were found (P = 0.432 and P = 0.592).
For Group 2 (pVAX-ORFF-Amastin) findings suggested the activation of a Th2 immune
response indicating the progression of the disease (Figure 6). Although, the differences between
cytokine profiles of Group 2 did not achieve statistical significance (P = 0.856). Group 2 was
also compared to negative controls, PBS and pVAX, but no statistically significant differences
were found (P = 0.247 and P = 0.372).
Group 3 (pVAX-BT-ICAM plus pVAX-ORFF-Amastin) exhibited a Th1 cytokine profile
(high IFN-γ, TNF-α, and IL-2 levels), but there was also an increased IL-4 expression (Figure 7).
For this group, no statistically significance differences were found between the cytokine profiles
(P = 0.376). Likewise, there was not found statistically significant differences when Group 3
was compared to negative controls, PBS (P = 0.221) and pVAX (P = 0.372).
For the negative controls, Group 4 (PBS) and Group 5 (pVAX), a mixed Th1/Th2
immune response is insinuated as well (Figure 8 and 9). However, there was no statistical
difference between the cytokine profiles of Group 4 (P = 0.715) or Group 5 (P = 0.602).
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CHAPTER V: DISCUSSION

To date, there are no approved vaccines for leishmaniasis. However, substantial efforts
have been done for the development of a vaccine (Coler & Reed, 2005; Khamesipour et al.,
2006; Requena et al., 2004). DNA or recombinant leishmaniasis vaccine candidates must be
composed of several antigens in order to affect the parasite survival mechanism (Dumonteil,
2007). The mixture of antigens should stimulate different layers of the immune responses and
exert a synergistic effect against target microorganism (Ahmed et al., 2009; Dumonteil et al.,
2003; Dunning, 2009). Hence, this present study used BT, ICAM, ORFF, and Amastin antigens
assembled in the pVAX backbone as a bicistronic plasmid in order examine this poly-antigen
vaccination approach.
A major finding for this study was that vaccine candidate given to Group 3 (pVAX-BTICAM-I plus pVAX-ORFF-Amastin) provided a partial protection and immunogenicity in
BALB/c mice. This group had the smallest mean difference in footpad thickness and this
protection can be associated with the activation of Th1-related cytokines (high levels of IL-2,
TNF-α, and IFN-γ). Similar patterns were observed in the study carried out by Dumonteil, et al
(2003). The progression leishmaniasis was followed for eight weeks noticing and BALB/c mice
immunized with the cocktail vaccine (GP63 plus GP46 plus CPb) developed smaller lesions than
those mice immunized with single-antigen vaccines or PBS. Another study using antigens
LACK, TSA, and LmSTI1 found that cocktail vaccines generated significantly higher levels of
protection in BALB/c mice (Ahmed et al., 2009). In general, investigators have found that the
immunogenicity of any anti-leishmaniasis vaccine is measured by its capability to induce an
efficient Th1 immune response, which is strongly associated with the protection of mice
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challenged with virulent Leishmania s.p. (Ahmed et al., 2009; Dumonteil et al., 2003). However,
the protective cytokine profile for Group 3 (pVAX-BT-ICAM-I plus pVAX-ORFF-Amastin)
was diminished by the activation of a Th2 immune response (high levels of IL-4). The presence
IL-4 correlates with the partial protection observed after the eight-week follow-up. It also
demonstrates that at the beginning of the trial this group had a high Th1 immune response which
was later on downregulated by the increasing levels of IL-4 marking the progression of the
disease.
Group 1 (pVAX-BT-ICAM) had the highest mean difference in footpad thickness when
compared to all experimental groups, this was correlated with the cytokine profiles obtained.
Group 1 (pVAX-BT-ICAM) showed higher levels of IFN-γ in the lymph node cells. As it was
previously mentioned, IFN-γ is critical for the activation of macrophages and it is responsible for
the killing of intracellular amastigotes (Bogdan & Rollinghoff, 1998). However, for Group 1,
TNF-α and IL-2 levels were low. Researchers have agreed that the three Th1 cytokines (IL-2,
TNF-α, and IFN-γ) must be activated in order to successfully resist the progression of the disease
(Kemp et al., 1998). Hence, the vaccine was not able to slow the progression of the disease. For
Group 2 (pVAX-ORFF-Amastin), IL-4 was activated at a higher level than any of the Th1related cytokines, meaning this vaccine candidate did not prevent the progression of the disease.
The negative control, Group 7 (PBS), showed the natural progression of cutaneous
leishmaniasis. As previously mentioned, BALB/c mice are susceptible to infection with L.
mexicana. Therefore, mice receiving PBS were expected to have an increased Th2 immune
response (Padigel et al., 2003). For the other negative control, Group 8 (pVAX), TNF-α and IL-2
levels were high. However, IFN-γ levels which are critical for the killing of the Leishmania
parasite were low. Therefore, the progression of the disease was not stopped.
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5.1 Conclusion
In conclusion, only vaccine formulation given to Group 3 (pVAX-BT-ICAM-I plus
pVAX-ORFF-Amastin) provided partial protection in BALB/c mice. At the end of the eighth
week, this vaccine candidate was able to decrease parasite burden better than single bicistronic
(pVAX-BT-ICAM or pVAX-ORFF-Amastin) vaccine candidates. Only Group 3 (pVAX-BTICAM-I + pVAX-ORFF-Amastin) had a predominant Th1 immune response by showing higher
levels of IFN-γ, in addition to increased levels of TNF-α, and IL-2. However, as previously
mentioned, this protective cytokine profile was reduced by the presence of IL-4 which correlates
to a partial protection observed after the eight-week follow-up. Hence, in order to successfully
attack L. mexicana, the vaccine must be composed of several antigens. Further studies need to be
conducted to support these findings as well as to evaluate the efficacy of this vaccine in other
Leishmania species that cause CL clinical form.
5.2 Strengths and Limitations
One of the strengths was that experimental and the control groups lived under the same
environmental conditions. Also, mice were randomly assigned into the different experimental
group and weekly mice’s footpad measurements were group blinded. Some of the limitations
include using a small sample size. However, a large sample size does not guarantee an optimal
trial protocol, a broad application of the trial results, or the validity of conclusions reached
(Institute of Medicine (US) Roundtable on Value & Science-Driven Health Care, 2010). In
addition, frozen cDNA was at 20oC instead of 80oC temperature for several hours due to
technical problems with the freezer. Therefore, the reading values in the QRT-PCR could have
been affected. Finally, Mean 2-ΔΔCT (following the Livak Method) was calculated by hand and
this could have introduced error in the analyses.
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Table 1. Immunization protocol for experimental and control groups
Experimental
Group
1
2

Experimental Condition

4

pVAX-BT-ICAM (100 µg)
pVAX-ORFF-Amastin (100 µg)
pVAX-BT-ICAM -I (100 µg) + pVAX-ORFF-Amastin (100
µg)
PBS (100 µl) – Negative control

5

pVAX (100 µg) – Negative control

3
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Mice
(n)
4
4
6
8
7

Table 2. Thermal cycler program for cDNA synthesis

Temperature
Time

Cycle 1 (1 cycle)
I
I
o
25 C
37oC
10 min

120 sec
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Cycle 2 (1 cycle)
II
85oC
5 minutes

Table 3. QRT-PCR thermal cycler program.
Cycle 1 (1 cycle)
I
Temperature 50oC
Time

3 min

Cycle 2 (50 cycles)
I
II
o
95 C
60oC
10 sec
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60 sec

Table 4. Descriptive statistics for the footpad inflammatory outcome.
Group (No. Mice)
1 (n = 4)
2 (n = 4)
3 (n = 6)
4 (n = 8)

Plasmid
pVAX-BT-ICAM
pVAX-ORFF-Amastin
pVAX-BT-ICAM-I plus pVAX-ORFF-Amastin
PBS (Negative control)

Mean
2.29
1.87
1.35
1.81

S.E.M
0.12
0.12
0.10
0.10

5 (n = 7)

pVAX (Negative control)

1.84

0.09
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Figure 1. Life cycle for cutaneous leishmaniasis (Centers for Disease Control (CDC), 2009). All
species of cutaneous leishmaniasis follow the same parasitic life cycle, alternating between the
promastigote and amastigote life stages. Infection begins with an infected female sandfly bite to
the mammal host. The sandfly becomes infected when feeding on the blood of an infected
individual or an animal reservoir host.
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NHE-1

pVAX-BT-ICAM
6.1 kb

BAM H1

PST-1

XBA-1
Figure 2. Schematic representation of pVAX backbone which encodes L. mexicana antigens BT
and ICAM. PCNV serves as the promoter for BT and ICAM, also assures that BT and ICAM are
expressed and read in ribosomes present in Leishmania life cycle. IRES reassure expression of
ICAM. NEH-I, BAM H1, PST-1 and XBA-1 are restrictive enzymes present in the plasmid.
BGHpA acts as the stop codon, whereas pUCORI is the start codon. Kanamycin is present in
order to segregate those cells that are able to become resistant to the antibiotic from those that
are not.
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NHE-1

pVAX-ORFF-Amastin
5.8 kb

BAM H1

PST-1

XBA-1
Figure 3. Schematic representation of pVAX backbone which encodes L. mexicana antigens
ORFF and Amastin. PCNV serves as the promoter for ORFF and Amastin, also assures that
ORFF and Amastin are expressed and read in ribosomes present in Leishmania life cycle. IRES
reassure expression of Amastin. NEH-I, BAM H1, PST-1 and XBA-1 are restrictive enzymes
present in the plasmid. BGHpA acts as the stop codon, whereas pUCORI is the start codon.
Kanamycin is present in order to segregate those cells that are able to become resistant to the
antibiotic from those that are not.
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Figure 4. Level of protection of BALB/c mice vaccinates with pVAX-BT-ICAM (1), pVAXORFF-Amastin (2), and pVAX-BT-ICAM plus pVAX-ORFF-Amastin (3) vs. Control groups;
PBS (4), and pVAX (5) over the eight weeks.
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Figure 5. Real Time PCR results. Mean 2-ΔΔCT for the lymph node cells using pVAX-BT-ICAM.
Only IFN-γ was activated at a higher level.
IL-2 ( x =0.47mm ± 0.41)
IL-4 ( x =7.54mm ± 5.90)
IFN-γ ( x =10.89mm ± 14.46)
TNF-α ( x =0.53mm ± 0.25)
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Figure 6. Real Time PCR results. Mean 2-ΔΔCT for the lymph node cells using pVAX-ORFFAmastin. The vaccine did induced protection in BALB/ mice.
IL-2 ( x =2.18mm ± 2.58)
IL-4 ( x =17.77mm ± 17.75)
IFN-γ ( x =0.39mm ± 0.47)
TNF-α ( x =0.69mm ± 1.08)

52

Lymph	
  Node:	
  Group	
  3	
  (pVAX-‐Bt-‐ICAM	
  +	
  pVAX-‐
ORFF-‐AmasOn)	
  
18.00	
  
16.00	
  
14.00	
  

Mean	
  2-‐∆∆CT	
  

12.00	
  
10.00	
  
8.00	
  

Mean	
  

6.00	
  
4.00	
  
2.00	
  
0.00	
  
IL-‐2	
  

IL-‐4	
  

IFN-‐γ	
  

TNF-‐α	
  

TaqMan	
  Probes	
  

Figure 7. Real Time PCR results. Mean 2-ΔΔCT for the lymph node cells using pVAX-BT-ICAM
+ pVAX-ORFF-Amastin. The vaccine induced partial protection in BALB/c mice.
IL-2 ( x =3.29 ± 3.20)
IL-4 ( x =7.57mm ± 8.02)
IFN-γ ( x =9.32mm ± 7.14)
TNF-α ( x =2.16mm ± 1.73)
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Figure 8. Real Time PCR results. Mean 2-ΔΔCT for the lymph node cells using PBS. The control
did not induced protection in BALB/c mice.
IL-2 ( x =1.07mm ± 1.17)
IL-4 ( x =2.66mm ± 4.84)
IFN-γ ( x =0.76mm ± 0.43)
TNF-α ( x =0.47mm ± 0.43)
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Figure 9. Real Time PCR results. Mean 2-ΔΔCT for the lymph node cells using pVAX. The
control did not induced protection in BALB/c mice.
IL-2 ( x =2.66mm ± 3.24)
IL-4 ( x =2.13mm ± 1.59)
IFN-γ ( x =0.73mm ± 0.77)
TNF-α ( x =4.64mm ± 8.34)
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